ProSciento and Antaros Medical Form Strategic Alliance to Incorporate Advanced Functional Imaging Techniques into NASH Clinical Research

SAN DIEGO and GOTHENBURG, Sweden, September 14, 2016 /PRNewswire/ – Prosciento, Inc., a full scope clinical R&D services provider focused exclusively on early phase clinical development programs in metabolic diseases, and Antaros Medical, an advanced clinical imaging research and methodology company, announced today a strategic collaboration to apply a broad range of non-invasive PET/MRI imaging techniques into pre- and postmarketing studies of cardiometabolic drugs and drug candidates.

Under the terms of the agreement, the companies plan to jointly design and conduct single and multi-center clinical studies that employ advanced PET/MRI applications to interrogate the mechanistic effects of novel therapeutics for diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD/NASH). Additionally, the partners plan to assess the potential of functional imaging readouts as non-invasive biomarkers to assess the prognosis and progression, as well as predict responses to experimental therapeutic interventions, in metabolic diseases such as NAFLD/NASH.

“Advanced functional imaging techniques can yield unique mechanistic insights to enhance decision making in cardiometabolic drug development across important areas of clinical research such as heart failure, microvascular dysfunction, atherosclerosis, myocardial fuel metabolism, tissue specific insulin resistance, diabetic nephropathy and hepatic steatosis, inflammation and fibrosis,” said Johannes Hulthe, MD, PhD, Antaros Medical CEO. “By partnering with Prosciento, a leading metabolism-focused CRO with extensive expertise and experience in diabetes, obesity and NAFLD/NASH, we have created an exciting opportunity to work collaboratively at the forefront of innovation in cardiometabolic clinical research.”

“We’re very pleased to have Antaros join our network of Metabolic Research PartnersTM, a group of select collaborators pursuing novel methodologies and setting high standards in cardiometabolic drug and device development,” said Dr. Marcus Hompesch, ProSciento’s CEO and Chairman of the Board. “The advanced functional imaging techniques developed by the Antaros team represent powerful methods for use in clinical trials, and valuable biomarkers indicative of disease activity and therapeutic responses, to better inform clinical and regulatory strategy and decision-making.”

About Antaros Medical

Antaros Medical is a drug development technology innovator based in the BioventureHub at AstraZeneca Gothenburg and in Uppsala, Sweden. Antaros Medical is pioneering new frontiers in innovative MRI and PET imaging techniques, leading to improved, evidence-based decision making in clinical drug development. Antaros Medical’s clients are spread across the globe and develop new treatments for patients suffering primarily from cardiovascular and metabolic diseases. For more information, visit

About ProSciento, Inc.

ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148

For business development inquires:

For clinical study enrollment inquires:
Tel: +1 (866) 308-7427


1 U.S. clinical trial data in diabetes, showing that ProSciento, Inc.’s early phase facility in Chula Vista has completed more Ph I/II T1DM and T2DM studies in the U.S. than any other clinical research site, provided by Citeline’s SiteTrove, a service offered by Informa Pharma Intelligence, April 2016